Department of Radiology, Duke University, Duke University Medical Center, Durham, NC, USA.
Korean J Radiol. 2024 Aug;25(8):698-705. doi: 10.3348/kjr.2024.0117. Epub 2024 Jul 4.
Ductal carcinoma in situ (DCIS) accounts for approximately 30% of new breast cancer diagnoses. However, our understanding of how normal breast tissue evolves into DCIS and invasive cancers remains insufficient. Further, conclusions regarding the mechanisms of disease progression in terms of histopathology, genetics, and radiology are often conflicting and have implications for treatment planning. Moreover, the increase in DCIS diagnoses since the adoption of organized breast cancer screening programs has raised concerns about overdiagnosis and subsequent overtreatment. Active monitoring, a nonsurgical management strategy for DCIS, avoids surgery in favor of close imaging follow-up to de-escalate therapy and provides more treatment options. However, the two major challenges in active monitoring are identifying occult invasive cancer and patients at risk of invasive cancer progression. Subsequently, four prospective active monitoring trials are ongoing to determine the feasibility of active monitoring and refine the patient eligibility criteria and follow-up intervals. Radiologists play a major role in determining eligibility for active monitoring and reviewing surveillance images for disease progression. Trial results published over the next few years would support a new era of multidisciplinary DCIS care.
导管原位癌(DCIS)约占新发乳腺癌诊断的 30%。然而,我们对于正常乳腺组织如何发展为 DCIS 和浸润性癌的认识仍然不足。此外,关于组织病理学、遗传学和放射学方面疾病进展机制的结论往往存在冲突,并对治疗计划有影响。此外,自采用有组织的乳腺癌筛查计划以来,DCIS 诊断的增加引起了人们对过度诊断和随后过度治疗的担忧。主动监测是一种针对 DCIS 的非手术管理策略,它避免了手术,而是通过密切的影像学随访来降低治疗强度,并提供更多的治疗选择。然而,主动监测面临的两个主要挑战是识别隐匿性浸润性癌和有浸润性癌进展风险的患者。随后,四项前瞻性主动监测试验正在进行中,以确定主动监测的可行性,并细化患者入选标准和随访间隔。放射科医生在确定主动监测的资格和审查疾病进展的监测图像方面发挥着重要作用。未来几年发表的试验结果将支持多学科 DCIS 护理的新时代。